GSA Capital Partners LLP Has $635,000 Stake in Alignment Healthcare, Inc. (NASDAQ:ALHC)

GSA Capital Partners LLP lowered its stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 35.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,720 shares of the company’s stock after selling 29,197 shares during the quarter. GSA Capital Partners LLP’s holdings in Alignment Healthcare were worth $635,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Deerfield Management Company L.P. Series C increased its stake in shares of Alignment Healthcare by 31.8% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company’s stock valued at $85,250,000 after acquiring an additional 2,630,788 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Alignment Healthcare by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after acquiring an additional 93,262 shares in the last quarter. Hood River Capital Management LLC increased its stake in shares of Alignment Healthcare by 6.4% in the 2nd quarter. Hood River Capital Management LLC now owns 3,106,690 shares of the company’s stock valued at $24,294,000 after acquiring an additional 185,854 shares in the last quarter. William Blair Investment Management LLC increased its stake in shares of Alignment Healthcare by 94.4% in the 2nd quarter. William Blair Investment Management LLC now owns 3,104,681 shares of the company’s stock valued at $24,279,000 after acquiring an additional 1,507,759 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Alignment Healthcare by 16.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,565,800 shares of the company’s stock valued at $12,245,000 after acquiring an additional 225,000 shares in the last quarter. Institutional investors own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Alignment Healthcare from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th. Stifel Nicolaus boosted their price target on shares of Alignment Healthcare from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Piper Sandler restated an “overweight” rating and set a $10.00 price target (up previously from $8.00) on shares of Alignment Healthcare in a research note on Tuesday, August 6th. TD Cowen boosted their price target on shares of Alignment Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Finally, Barclays boosted their price target on shares of Alignment Healthcare from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.33.

Insider Buying and Selling

In related news, insider Dawn Christine Maroney sold 7,074 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $9.02, for a total value of $63,807.48. Following the transaction, the insider now directly owns 1,789,023 shares of the company’s stock, valued at approximately $16,136,987.46. The trade was a 0.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John E. Kao sold 90,000 shares of the business’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $11.33, for a total transaction of $1,019,700.00. Following the completion of the transaction, the chief executive officer now directly owns 2,543,100 shares in the company, valued at $28,813,323. This trade represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 515,507 shares of company stock valued at $6,158,835. 6.60% of the stock is owned by insiders.

Alignment Healthcare Stock Performance

NASDAQ ALHC opened at $11.17 on Tuesday. Alignment Healthcare, Inc. has a 1 year low of $4.46 and a 1 year high of $14.25. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -14.50 and a beta of 1.45. The company has a fifty day moving average price of $11.62 and a 200-day moving average price of $9.45.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Tuesday, October 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. The firm had revenue of $692.43 million during the quarter, compared to analyst estimates of $662.11 million. During the same quarter in the prior year, the business posted ($0.19) EPS. The business’s revenue was up 51.6% compared to the same quarter last year. As a group, equities research analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.